Transcript Company presentation continous

InBio Ltd.___________________________________
InBio Ltd.
ANTIBODIES FOR THERAPEUTIC
AND DIAGNOSTIC APPLICATIONS
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
InBio Ltd.___________________________________
Facts on InBio
•Established in Tallinn, 1999
•General business idea: to develop new effective and
selective skin cancer therapeutics and diagnostics.
•The company was initiated by a group of scientists of
National Institute of Chemical Physics and Biophysics
and Karolinska Institute, Sweden
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
InBio Ltd.___________________________________
Financial results (EUR):
Turnover
1999
10000
2000
225000
2001
190000
Profit before taxes
-2000
19000
8000
Equity
Employees
3300
2
3300
4
3300
7
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
InBio Ltd.___________________________________
Background for product development
•Cancer is the second most common cause of death in
the developed world
•The limits of usefulness are being approached for
conventional therapies and further advances will
require principally new approaches
•The foreseen products of our company are
prototypes of new anti-cancer drugs that are
characterised by:
-high degree of selectivity
-efficient delivery
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
InBio Ltd.___________________________________
What is antibody?
•Antibodies are made by a class of white blood cells
•They are naturally present in the blood
•Biological function is to perform defence functions
•Each antigen causes the formation of a specific
antibody
•Recombinant DNA technology allows the engineer
antibodies
•It is possible to produce complete antibodies in cell
culture systems.
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
InBio Ltd.___________________________________
Reasons to use antibodies in drug development
•Can be rationally designed and easily made
•Can be engineered to add fragmenmts that enhance their
therapeutic potential
•Have no intrinsic toxicity as based on the natural
molecules
• Monoclonal antibodies (mAbs)will not fail at the drug
safety testing (phase I clinical trial stages)
•Technology is now advanced enough for therapeutic
applications of mAbs
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
InBio Ltd.___________________________________
What is new in our technology ?
• Our technology combines two different platforms:
1. Monoclonal antibodies against cancer-specific
antigens
2. Modification of antibody sequence to make these
mAbs membrane permeable
• Such approach helps to utilise intracellular cancerspecific targets that can not be usually reached
• Focus on skin cancer, first targets are GLI proteins
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
InBio Ltd.___________________________________
What are GLI proteins?
• GLI proteins are gene switches
• GLI proteins are involved in development and
lead cells to divide
• Abnormal activation of GLI proteins lead to
cancer
• GLI proteins represent an attractive target
for anticancer drug development
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
InBio Ltd.___________________________________
Gene switch turned on
Cancer develops
Cancer
development
inhibited
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
InBio Ltd.___________________________________
Cell penetrating peptides (CPPs)
•Family of peptides capable to
penetrate cellular membranes
•We can transport the
following molecules into cells
using CPP technology:
-other peptides
-nucleic acids
-proteins e.g. antibodies
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
InBio Ltd.___________________________________
World antibody market:
•Currently more than 200 monoclonal antibodies are in development
•Targeted disorders include cancer, heart disease, infectious diseases and
autoimmune diseases
•Market is still in its inception stage,
•Market size estimated at nearly $2.8 billion in 1999,
•Market forecast growth to almost $9.8 billion in 2004.
•Expected therapeutic antibody average annual growth rate is projected
at 21,8%
•Diagnostic/therapeutic antibody AAGR will grow at fast nearly 50% rate
Main Target Markets for InBio:
•Scandinavian Market
•U.S. market
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
InBio Ltd.___________________________________
Timing and positioning
•Antibody based drugs are in the position of significant
commercial growth
•InBio enters the market at the moment when all
developers seek for new approaches
•InBio has new technology to make antibodies more
effective
•InBio has involved outstanding specialists from all fields
that are required to accomplish our business plan
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826
InBio Ltd.___________________________________
•Benefits for the investor:
Will invest in profitable business at evolving market
Will invest in area that is significantly improving the
well-being of the mankind
Will get possession rights of a unique know-how and
new technologies that will realise in new type of
therapeutic and diagnostic tools
Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826